Keyphrases
Hemophilia
100%
Bleeding
100%
BAY 94-9027
100%
Bleeding Rate
100%
Standard Half-life FVIII
100%
Twice Daily
50%
Recombinant Factor VIII
33%
Dosing Regimen
16%
Three-period
16%
Dose Rate
16%
Severe Haemophilia A
16%
Treatment Duration
16%
Treatment Regimen
16%
Previously Treated Patients
16%
Weekly Dosing
16%
Nonacog beta Pegol
16%
Prophylaxis Treatment
16%
Bleeding Phenotype
16%
Extended Half-life
16%
Annualized Bleeding Rate
16%
Joint Bleeding
16%
Infusion Frequency
16%
Standard Half-life
16%
Bleeding Prevention
16%
Factor VIIIa
16%
Nursing and Health Professions
Half Life Time
100%
Bleeding
100%
Ciclonicate
100%
Patient with Hemophilia
100%
Haemophilia A
100%
Infusion
40%
Blood Clotting Factor 8
40%
Post Hoc Analysis
20%
Randomization
20%
Hemarthrosis
20%
Recombinant Blood Clotting Factor 8
20%
Pharmacology, Toxicology and Pharmaceutical Science
Bleeding
100%
Ciclonicate
100%
Haemophilia A
100%
Blood Clotting Factor 8
40%
Recombinant Blood Clotting Factor 8
20%
Hemarthrosis
20%